抗凝预防心房颤动患者缺血性卒中与神经认知损伤:BRAIN-AF随机临床试验
BRAIN-AF是一项多中心、双盲、安慰剂对照试验,纳入卒中低危(CHA2DS2-VASc评分0或1,女性性别不计分)的心房颤动患者,随机接受利伐沙班15 mg每日一次或安慰剂。主要复合终点为认知下降(蒙特利尔认知评估下降≥2分)、卒中或伴运动缺陷或失语症的短暂性脑缺血发作。试验在计划中期分析达到预设无效标准后提前终止,实际入组1235例(计划1424例),中位随访3.7年,主要终点年发生率利伐沙班7.0% vs 安慰剂6.4%,风险比1.10(95%CI 0.86-1.40;P=0.46)。
要点
- 卒中低危心房颤动患者中,利伐沙班15 mg每日一次未显著降低认知下降、卒中或短暂性脑缺血发作复合终点。
- 主要终点年发生率利伐沙班7.0% vs 安慰剂6.4%,HR 1.10(95%CI 0.86-1.40;P=0.46)。
- 大出血利伐沙班组2例(每年0.09%)vs 安慰剂组5例(每年0.21%)。
核心结论
- 尽管卒中低危心房颤动患者中认知下降发生率较高,但测试低剂量利伐沙班预防卒中、短暂性脑缺血发作和认知下降的BRAIN-AF试验因无效而提前终止。
研究设计与样本
- 多中心、双盲、安慰剂对照随机临床试验,纳入卒中低危(CHA2DS2-VASc评分0或1,女性性别不计分)的心房颤动患者,按1:1随机接受利伐沙班15 mg每日一次或安慰剂。
- 计划入组1424例,实际入组1235例(男919例;女316例);中位随访3.7年。
- 主要终点为认知下降(蒙特利尔认知评估下降≥2分)、卒中或伴运动缺陷或失语症的短暂性脑缺血发作的复合终点。
主要发现
- 中位随访3.7年期间,主要终点发生于256例(20.7%)受试者。
- 主要终点年发生率利伐沙班组7.0% vs 安慰剂组6.4%,HR 1.10(95%CI 0.86-1.40;P=0.46)。
- 条件效能分析显示,若试验继续至计划的总共410个事件,获得统计学显著治疗效应的概率为1.2%。
- 大出血利伐沙班组2例(每年0.09%)vs 安慰剂组5例(每年0.21%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验在计划中期分析达到预设无效标准后提前终止,实际入组1235例,低于计划的1424例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA2DS2-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86-1.40); P = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: NCT02387229 .
引用
- Rivard L, Khairy P, Talajic M, et al. Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial. Nat Med. 2026. PMID: 41501492. doi:10.1038/s41591-025-04101-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。